| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00833eb7e281d7a79a641a04cbee57a1 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D243-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D245-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D223-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D225-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-033
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc194ed3e36572b23795049096e60a73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a49ec20b6bebee803da7902279ee4d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2703ca9c28fd9c492a7a453fd927240e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cd07891c823f1ee660ddd666a706deb |
| publicationDate |
2019-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019190331-A1 |
| titleOfInvention |
Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders |
| abstract |
AKR1C3-activated prodrugs of Formula (I), pharmaceutical compositions comprising prodrugs of Formula (I), and their use in the treatment of hyperproliferative diseases such as cancer and for cell ablation. The compounds of the invention are able to penetrate neoplasm tissue and be selectively reduced to an active (cytotoxic) form by contact with an AKR1C3 enzyme found in the neoplasm. This active form is therefore able to ablate AKR1C3-expressing target cells of the neoplasm and therefore has particular utility in the treatment of cancer and other hyperproliferative disorders. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022183483-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022048492-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023046060-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021110085-A1 |
| priorityDate |
2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |